Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUDY7H)

Drug Name

PDC-31 Drug Info

Synonyms

PDC-31 (nasal, dysmenorrhea); PDC-31 (nasal, dysmenorrhea), PDC; THG-113 (nasal formulation, primary dysmenorrhea), PDC Biotech; THG-113.31 (nasal, primary dysmenorrhea), PDC Biotech

Indication

Disease Entry	ICD 11	Status	REF
Dysmenorrhea	GA34.3	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMUDY7H

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prostaglandin F2-alpha receptor (PTGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[2]
Latanoprost	DMI5OXG	Ocular hypertension	9C61.01	Approved	[3]
BOL-303259-X	DM2EXC5	Open-angle glaucoma	9C61	Approved	[4]
Tafluprost	DMFC41K	Glaucoma/ocular hypertension	9C61	Approved	[5]
Carboprost Tromethamine	DMS3508	Abortion	JA00	Approved	[6]
Travoprost	DM20K91	Ocular hypertension	9C61.01	Approved	[7]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[8]
PGF2ALPHA-IE	DM5DAP3	Glaucoma/ocular hypertension	9C61	Phase 3	[9]
ONO-9054	DM5O6GC	Glaucoma/ocular hypertension	9C61	Phase 2	[10]
PDC-41	DM74YO8	Dysmenorrhea	GA34.3	Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin F2-alpha receptor (PTGFR)	TTT2ZAR	PF2R_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 344).
2	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
3	PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
4	Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
8	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
9	Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
10	IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
11	THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.